Carterra

Carterra is a leading provider of innovative technologies designed to accelerate the discovery of novel therapeutic candidates. Carterras high throughput LSA, LSA-XT, and Ultra platforms for monoclonal antibody (mAb) and small molecule screening and characterization combine patented microfluidics technology with real-time High-Throughput Surface Plasmon Resonance (HT-SPR) and industry-leading analysis and visualization software. These systems deliver up to 100 times the throughput in 10% of the time while using only 1% of the sample compared to existing label-free platforms. The LSA-XT and Ultra instruments introduce enhancements to Carterras flagship product, the LSA, increasing sensitivity and enabling new applications in biotherapeutic discovery...

Biotechnology,antibody discovery,label-free,epitope binning,kinetic characterization,spr,epitope mapping,cancer,neuroscience,infectious disease,immunooncology,antibody development,b-cell enrichment,phage display,protein-protein,hybridoma ,b cell cloning ,covid19,immunity monitoring ,vaccine research ,serology ,and hybridoma screening

Carterra operates in the Biotechnology industry.

Carterra's revenue is 11m - 100m

Carterra has 51 - 200 employees.